Physician profile
Robert Singh
NPI 1154447175
$778.25
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $55.10 · 2021: $164 · 2022: $136 · 2023: $22.67 · 2024: $21.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $236.39 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $150.85 | 2019 | |
| Grifols USA, LLC | $64.75 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.71 | 2021-2022 | |
| Janssen Biotech, INC. | $56.09 | 2019-2020 | |
| Biogen, INC. | $50.19 | 2021-2022 | |
| Allergan, INC. | $28.07 | 2019 | |
| Horizon Therapeutics Plc | $26.89 | 2021 | |
| Glaxosmithkline, LLC. | $22.67 | 2023 | Nucala |
| Lilly USA, LLC | $21.64 | 2024 | Zepbound |
| Amgen INC. | $21.34 | 2022 | |
| Genentech USA, INC. | $20.41 | 2022 | |
| Merck Sharp & Dohme LLC | $16.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.